Money Concepts Capital Corp Increases Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Money Concepts Capital Corp lifted its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 4.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,031 shares of the company’s stock after buying an additional 848 shares during the period. Money Concepts Capital Corp’s holdings in Structure Therapeutics were worth $570,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Wellington Management Group LLP raised its holdings in shares of Structure Therapeutics by 2.9% during the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after buying an additional 221,851 shares in the last quarter. FMR LLC raised its holdings in shares of Structure Therapeutics by 6.7% during the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after buying an additional 383,635 shares in the last quarter. Janus Henderson Group PLC raised its holdings in shares of Structure Therapeutics by 18.0% during the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after buying an additional 602,609 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of Structure Therapeutics by 196.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock valued at $54,348,000 after buying an additional 820,589 shares in the last quarter. Finally, Vestal Point Capital LP raised its holdings in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after buying an additional 590,000 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GPCR has been the topic of several recent research reports. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, JMP Securities restated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $30.02 on Friday. The firm has a market cap of $1.72 billion, a P/E ratio of -40.57 and a beta of -2.76. Structure Therapeutics Inc. has a fifty-two week low of $23.50 and a fifty-two week high of $62.74. The business’s 50 day moving average price is $29.40 and its 200-day moving average price is $35.03.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.